Invariant chain expression in gastric cancer

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Invariant chain (Ii) is a chaperone molecule inhibiting antigen binding to HLA class II.
• Tumor cells overexpressing Ii may evade immune attack by suppressing host immunity.
• The link between Ii expression and clinicopathological factors in gastric cancer is not well understood.

Purpose of the Study:

• To investigate the relationship between invariant chain (Ii) expression in tumor cells and clinicopathological factors in gastric cancer.
• To determine if Ii expression serves as a prognostic marker in gastric cancer patients.

Main Methods:

• Immunohistochemical staining using anti-CD74 (Ii) and anti-HLA-DR antibodies on tumor samples from 126 gastric cancer patients.
• Correlation analysis between Ii expression and clinicopathological factors, including tumor invasion depth, clinical stage, and HLA-DR expression.
• Evaluation of surgical outcomes in relation to Ii expression levels.

Main Results:

• Invariant chain (Ii) expression was detected in 48 of 126 gastric cancer patients.
• Ii expression showed a negative correlation with tumor invasion depth and clinical stage.
• A negative correlation was observed between Ii expression and HLA-DR expression.
• Patients with negative Ii expression had significantly better surgical outcomes compared to those with positive Ii expression (P<0.05).

Conclusions:

• Invariant chain (Ii) expression in gastric cancer is associated with clinicopathological features and surgical outcomes.
• Ii expression negatively correlates with tumor invasion depth and HLA-DR expression.
• Invariant chain (Ii) may function as a prognostic factor in gastric cancer, potentially through immune response suppression.